CASP1 and COVID-19: Herein, we expand this knowledge by showing that approximately 10% of circulating CD14highCD16− inflammatory monocytes from COVID-19 patients demonstrate ASC/Caspase-1/4/5 inflammasome complex formation, which appears to persist after short-term recovery.